An Oral GnRH Antagonist to Treat Mild Autonomous Cortisol Excess (MACE) Due to Adrenal Adenomas in Postmenopausal Women
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine if treatment with Elagolix will improve
body weight, waist circumference, muscle strength, cortisol secretion, blood glucose,
cholesterol, and bone quality as well as mood and quality of life in a female patient with
mild hypercortisolism from adrenal overproduction of cortisol. Many people with adrenal
nodules, or non-cancerous growths in the adrenal glands, have mildly elevated cortisol
levels. Cortisol is a hormone normally made by the adrenal glands. It is increasingly being
recognized that even mild elevations in cortisol levels can negatively impact blood glucose
levels, serum cholesterol levels, weight and other metabolic parameters. This can lead to an
increase in risk for cardiovascular disease. The study team is trying to determine if the
medication Elagolix might be an effective treatment for post-menopausal females with mild
hypercortisolism. Elagolix is a medication used to treat a medical condition called
endometriosis by decreasing the body's production of sex hormones. Growth of adrenal adenomas
is thought to be driven by such sex hormones. Therefore, by decreasing production of these
hormones, the study team hopes to treat hypercortisolism caused by adrenal adenomas.